No connection

Search Results

IMMP

BEARISH
$0.31 Live
Immutep Limited · NASDAQ
$0.3 52W Range $3.53

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 12, 2026
Market cap
$46.14M
P/E
N/A
ROE
-61.8%
Profit margin
N/A
Debt/Equity
0.01
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
90%
Immutep Limited presents a high-risk profile characterized by a Piotroski F-Score of 4/9, indicating only marginal financial stability. While the company shows strong YoY revenue growth of 91.50% and maintains a healthy current ratio of 2.97, these are overshadowed by a catastrophic operating margin of -763.71% and a total collapse in share price. The stock has lost approximately 78% of its value over the last year and 88.8% in the last month, signaling a severe lack of market confidence and a bearish technical trend of 0/100.

Key Strengths

Strong YoY revenue growth of 91.50%
Very low leverage with a Debt/Equity ratio of 0.01
Strong short-term liquidity (Current Ratio: 2.97)
Low absolute debt levels
Positive revenue trajectory typical of early-stage biotech milestones

Key Risks

Extreme cash burn evidenced by -763.71% operating margin
Severe price devaluation (down from 52-week high of $3.53 to $0.31)
Negative ROE (-61.85%) and ROA (-32.10%)
Micro-cap volatility and low market capitalization ($0.05B)
Complete lack of profitability with a negative forward P/E

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
26
Weak
Value
30
Future
45
Past
5
Health
50
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Catastrophic price performance, Unsustainable operating losses, Extreme technical bearishness
Confidence
95%
Value
30/100

P/B is elevated for a company with no profit; Graham Number is N/A due to lack of earnings.

Positives
  • Low debt
Watchpoints
  • High Price/Book (6.75)
  • No earnings for P/E or Graham calculation
Future
45/100

Growth is present but not translating to operational efficiency.

Positives
  • High revenue growth (91.5%)
Watchpoints
  • Negative forward P/E
  • High burn rate
Past
5/100

Consistent and accelerating value destruction across all timeframes.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change: -91.1%
  • 1M Change: -88.8%
Health
50/100

Balance sheet is clean (low debt), but the income statement is hemorrhaging cash.

Positives
  • Low Debt/Equity
  • Strong Current Ratio
Watchpoints
  • Piotroski F-Score 4/9 (Stable/Weak)
  • Extreme operating losses
Dividend
0/100

Typical for biotech; no yield available.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 strength score

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.31

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for IMMP and closest competitors.

Updated 2026-04-10
IMM
Immutep Limited
Primary
5Y
-91.1%
3Y
-80.6%
1Y
-78.0%
6M
-84.6%
1M
-88.8%
1W
-13.9%
ALG
Aligos Therapeutics, Inc.
Peer
5Y
-98.8%
3Y
-77.7%
1Y
-26.4%
6M
-25.8%
1M
+1.5%
1W
+8.4%
ARA
Accuray Incorporated
Peer
5Y
-93.2%
3Y
-87.0%
1Y
-78.7%
6M
-76.4%
1M
-27.4%
1W
-24.4%
ELU
Elutia Inc.
Peer
5Y
-91.4%
3Y
-20.8%
1Y
-53.7%
6M
+28.2%
1M
-2.6%
1W
+4.6%
APL
Apollomics, Inc.
Peer
5Y
-98.0%
3Y
-98.1%
1Y
+148.8%
6M
+191.4%
1M
-0.5%
1W
-0.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-1.42
PEG Ratio
N/A
P/B Ratio
6.75
P/S Ratio
5.82
EV/Revenue
45.88
EV/EBITDA
-4.41
Market Cap
$46.14M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -763.71%
Gross Margin N/A
ROE -61.85%
ROA -32.1%

Growth

Revenue and earnings growth rates

Revenue Growth +91.5%
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.01
Low debt
Current Ratio
2.97
Strong
Quick Ratio
2.91
Excellent
Cash/Share
$0.07

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.1B
Debt/Equity
0.49x

Quarterly Earnings History

EPS performance vs analyst estimates

2026-09-02
$N/A

Healthcare Sector Comparison

Comparing IMMP against 264 companies in the Healthcare sector (20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-61.85%
This Stock
vs
-46.09%
Sector Avg
+34.2% (Excellent)
Debt to Equity
0.01
This Stock
vs
4.1
Sector Avg
-99.7% (Less Debt)
Revenue Growth
91.5%
This Stock
vs
88.16%
Sector Avg
+3.8% (Growing)
Current Ratio
2.97
This Stock
vs
3.58
Sector Avg
-16.9% (Weaker)

Similar Companies

Peer comparison within the same industry

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
HOLD
0 analysts
Citizens
2026-03-13
down
Market Outperform Market Perform
Baird
2026-03-13
down
Outperform Neutral
Citizens
2026-02-23
init
Market Outperform
Citizens
2026-02-17
init
Market Outperform

Past News Coverage

Recent headlines mentioning IMMP from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile